30 November 2023FeaturesBiotechnologyMarisa Woutersen

Scientists and IP: Avoiding the pitfalls of publishing research

Publishing scientific findings after a patent application is filed can lead to more than a few potential pitfalls as a panel at LSPN Europe last week explored.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More on this story

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More on this story

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More features

BMS blocks biosimilar version of blockbuster cancer drug in India

WATCH: Protecting life science innovations involving big data, AI and machine learning

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market